TY - JOUR
T1 - Associations of Early Completion of Advance Directives with Key End-of-Life Quality Measures
T2 - Analysis of an ASCO Quality Oncology Practice Initiative Patient Cohort
AU - Power, Steve
AU - Bickel, Kathleen
AU - Chen, Ronald C.
AU - Chiang, Anne C.
AU - Garrett-Mayer, Liz
AU - Makhoul, Issam
AU - Mougalian, Sarah S.
AU - Shapiro, Charles L.
AU - Siegel, Robert
AU - Smith, Cardinale
AU - Rocque, Gabrielle B.
AU - Kozlik, Mary May
AU - Crist, Stéphanie T.S.
AU - Kamal, Arif
N1 - Publisher Copyright:
© American Society of Clinical Oncology.
PY - 2023/4/1
Y1 - 2023/4/1
N2 - PURPOSE:Despite the growing calls for early and ubiquitous completion of advance directives (ADs), studies exploring links between AD completion and their impact on outcomes of patients with cancer have mixed conclusions. We used the ASCO Quality Oncology Practice Initiative (QOPI) registry to compare end-of-life (EOL) quality measures and the effect of QOPI certification among patients with and without early AD completion, defined as completion within the first three oncology visits after cancer diagnosis.METHODS:Deidentified patient-level data were analyzed from the QOPI database from 2015 through 2017. Associations were assessed using Chi-square tests between early AD completion and patient enrollment in hospice < 7 days before death, chemotherapy receipt in the last 14 days of life, or with emergency room visits or intensive care unit admissions in the last 30 days of life.RESULTS:Data from 31,558 patients eligible for the AD question were analyzed. Patients treated at QOPI-certified practices had higher rates of early AD completion than patients at non-certified practices. Early AD completion was not associated with differences in hospice enrollment for < 7 days before death, chemotherapy receipt in the last 14 days of life, or emergency room visits or intensive care unit encounters in the last 30 days of life.CONCLUSION:The study found that QOPI certification is associated with higher rates of early AD completion. However, early AD completion was not associated with recognized EOL quality measures. Future research should focus on the timing, frequency, and content of AD conversations to demonstrate the impact on care at the EOL.
AB - PURPOSE:Despite the growing calls for early and ubiquitous completion of advance directives (ADs), studies exploring links between AD completion and their impact on outcomes of patients with cancer have mixed conclusions. We used the ASCO Quality Oncology Practice Initiative (QOPI) registry to compare end-of-life (EOL) quality measures and the effect of QOPI certification among patients with and without early AD completion, defined as completion within the first three oncology visits after cancer diagnosis.METHODS:Deidentified patient-level data were analyzed from the QOPI database from 2015 through 2017. Associations were assessed using Chi-square tests between early AD completion and patient enrollment in hospice < 7 days before death, chemotherapy receipt in the last 14 days of life, or with emergency room visits or intensive care unit admissions in the last 30 days of life.RESULTS:Data from 31,558 patients eligible for the AD question were analyzed. Patients treated at QOPI-certified practices had higher rates of early AD completion than patients at non-certified practices. Early AD completion was not associated with differences in hospice enrollment for < 7 days before death, chemotherapy receipt in the last 14 days of life, or emergency room visits or intensive care unit encounters in the last 30 days of life.CONCLUSION:The study found that QOPI certification is associated with higher rates of early AD completion. However, early AD completion was not associated with recognized EOL quality measures. Future research should focus on the timing, frequency, and content of AD conversations to demonstrate the impact on care at the EOL.
UR - http://www.scopus.com/inward/record.url?scp=85152488005&partnerID=8YFLogxK
U2 - 10.1200/OP.22.00464
DO - 10.1200/OP.22.00464
M3 - Article
C2 - 36669136
AN - SCOPUS:85152488005
SN - 2688-1527
VL - 19
SP - E520-E526
JO - JCO Oncology Practice
JF - JCO Oncology Practice
IS - 4
ER -